Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion official investor newsroom · Indexed industry source record · Source published: Thu Oct 15 2026 12:45:47 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 15 2026 13:07:49 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration October 15, 2026 at 8:45 AM EDT PDF Version Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.